Evidence mapPaperPMID 18256578Full record

ReviewJournal of clinical hypertension (Greenwich, Conn.)2008

State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension.

Pantelis A Sarafidis, George L Bakris

Registry-linked trialAbstract readReview
In one paragraph

Review in Journal of clinical hypertension (Greenwich, Conn.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02887677 (A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02887677 phase4terminatedstarted 2016, after this paper: background citation

A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes

Ran2016Enrolled85Registered outcomes9Posted comparisons0ConditionsDiabetes MellitusArmsdapagliflozin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. ASH position paper: treatment of hypertension in patients with diabetes-an update.Journal of clinical hypertension (Greenwich, Conn.) · 2008
    Guideline
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Review
  19. Review
  20. The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Pantelis A SarafidisSection of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Greece.
George L Bakris

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An improvement in the awareness and treatment of hypertension in the United States has occurred, resulting in the best control rates in the world, which unfortunately are far below the goals of Healthy People 2000 or 2010. This failure to achieve blood pressure (BP) goals is attributed to many factors, including an aging population, higher prevalence of kidney disease and obesity, high salt intake, physician inertia to increase dose and number of antihypertensive medications prescribed, and patient nonadherence with medication regimens. Resistant hypertension is defined as a failure to achieve goal BP in patients who adhere to full doses of an appropriate antihypertensive regimen of 3 drugs that includes a diuretic. The problem of resistant hypertension is projected to increase as the population ages. Efforts on the part of the Veterans Administration hospitals and others clearly indicate that a system can be implemented to help increase the percentage of persons in whom BP goal is achieved and reduce the prevalence of resistant hypertension. Medications specific to the problem of resistant hypertension are also under development. This review analyzes the status of hypertension control in the United States, the frequency of associated diseases, and adherence to guidelines; it further discusses strategies to reduce the prevalence of resistant hypertension.

Indexed as

Age FactorsAntihypertensive AgentsAwarenessGuideline AdherenceHumansHypertensionPatient CompliancePrevalenceRisk FactorsSeverity of Illness IndexTreatment OutcomeTreatment RefusalUnited StatesAntihypertensive Agents

Identifiers

PMID18256578
PMCPMC8110159

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.